Immuneering Corp Cl A (IMRX)

$2.56 -0.21 (-7.58%)
Market Cap 92.12M
Revenue (ttm) 0.00
Net Income (ttm) -61.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,730,100
Avg Vol 1,073,476
Day's Range N/A - N/A
Shares Out 35.99M
Stochastic %K 63%
Beta 0.01
Analysts Strong Sell
Price Target $11.08

Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Cor...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 500 8080
Address:
245 Main Street, Second Floor, Cambridge, United States
TrendAM
TrendAM Jun. 23 at 11:22 AM
$RBNE $GPUS $IMRX $RELI - Heading for new weekly high !
0 · Reply
Rybod30
Rybod30 Jun. 23 at 11:22 AM
$IMRX Holding $2 gonna be tough…
0 · Reply
TrendAM
TrendAM Jun. 23 at 11:17 AM
$OP Backup again on $RBNE and added $GPUS $IMRX
0 · Reply
TrendAM
TrendAM Jun. 23 at 11:01 AM
$OP added. Added more $GPUS $IMRX $RELI for big rebound play today
0 · Reply
davis8uni
davis8uni Jun. 23 at 3:10 AM
$IMRX
0 · Reply
sam92
sam92 Jun. 22 at 11:25 PM
$IMRX
0 · Reply
winners18
winners18 Jun. 22 at 3:48 PM
$IMRX
1 · Reply
davis8uni
davis8uni Jun. 22 at 1:35 PM
$IMRX
0 · Reply
davis8uni
davis8uni Jun. 21 at 11:27 PM
$IMRX
0 · Reply
StockScanners
StockScanners Jun. 21 at 7:53 PM
$IMRX imrx reached 3.09
0 · Reply
Latest News on IMRX
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Jun 17, 2025, 6:00 AM EDT - 6 days ago

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Jun 16, 2025, 8:00 AM EDT - 6 days ago

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Immuneering to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 24 days ago

Immuneering to Present at the Jefferies Global Healthcare Conference

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

May 5, 2025, 4:05 PM EDT - 6 weeks ago

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 8:00 AM EDT - 2 months ago

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Immuneering Corporation Announces Grant of Inducement Award

Mar 21, 2025, 4:30 PM EDT - 3 months ago

Immuneering Corporation Announces Grant of Inducement Award

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 20, 2025, 4:05 PM EDT - 3 months ago

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Mar 20, 2025, 7:00 AM EDT - 3 months ago

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 4:05 PM EST - 4 months ago

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Why Is Immuneering Stock Trading Higher On Tuesday?

Jan 7, 2025, 9:28 AM EST - 5 months ago

Why Is Immuneering Stock Trading Higher On Tuesday?

Immuneering Launches Pancreatic Cancer Advisory Board

Dec 19, 2024, 8:00 AM EST - 6 months ago

Immuneering Launches Pancreatic Cancer Advisory Board

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Dec 13, 2024, 2:10 PM EST - 6 months ago

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

FOLD

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Dec 12, 2024, 8:00 AM EST - 6 months ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 7 months ago

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 13, 2024, 4:05 PM EST - 7 months ago

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Sep 12, 2024, 4:05 PM EDT - 10 months ago

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 6, 2024, 4:05 PM EDT - 11 months ago

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Jul 31, 2024, 4:05 PM EDT - 11 months ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

May 7, 2024, 4:05 PM EDT - 1 year ago

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Immuneering Recognizes Melanoma Awareness Month

May 6, 2024, 4:30 PM EDT - 1 year ago

Immuneering Recognizes Melanoma Awareness Month

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Apr 9, 2024, 12:00 PM EDT - 1 year ago

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 4:05 PM EDT - 1 year ago

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Mar 27, 2024, 8:00 AM EDT - 1 year ago

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Mar 19, 2024, 2:19 AM EDT - 1 year ago

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Mar 14, 2024, 7:00 AM EDT - 1 year ago

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Immuneering Appoints Thomas J. Schall, Ph.D.

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Immuneering Appoints Thomas J. Schall, Ph.D.

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Mar 6, 2024, 8:00 AM EST - 1 year ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

BLRX CADL ONCY

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 5:00 PM EST - 1 year ago

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

Mar 4, 2024, 8:00 AM EST - 1 year ago

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Mar 1, 2024, 8:00 AM EST - 1 year ago

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Feb 20, 2024, 8:00 AM EST - 1 year ago

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Immuneering Announces Participation in February Investor Conferences

Feb 1, 2024, 8:00 AM EST - 1 year ago

Immuneering Announces Participation in February Investor Conferences

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Dec 12, 2023, 8:00 AM EST - 1 year ago

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 4:05 PM EST - 1 year ago

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 4:05 PM EST - 1 year ago

Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates

Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

Oct 12, 2023, 4:05 PM EDT - 1 year ago

Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 4, 2023, 4:05 PM EDT - 1 year ago

Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Immuneering to Present at the Morgan Stanley Healthcare Conference

Sep 6, 2023, 8:00 AM EDT - 1 year ago

Immuneering to Present at the Morgan Stanley Healthcare Conference

Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates

Aug 3, 2023, 4:05 PM EDT - 2 years ago

Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates

Immuneering Corp.: Early Stage Promise, But Long-Term Investment

Jul 7, 2023, 5:55 PM EDT - 2 years ago

Immuneering Corp.: Early Stage Promise, But Long-Term Investment

Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors

Immuneering to Present at the Jefferies Healthcare Conference

May 30, 2023, 8:00 AM EDT - 2 years ago

Immuneering to Present at the Jefferies Healthcare Conference

Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

May 4, 2023, 4:05 PM EDT - 2 years ago

Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

Immuneering Announces $30 Million Underwritten Offering

Apr 18, 2023, 9:24 AM EDT - 2 years ago

Immuneering Announces $30 Million Underwritten Offering

Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline

Apr 18, 2023, 9:00 AM EDT - 2 years ago

Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline

Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference

Apr 12, 2023, 4:05 PM EDT - 2 years ago

Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference

Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

Apr 5, 2023, 8:00 AM EDT - 2 years ago

Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

Immuneering Appoints Harold E. Brakewood as Chief Business Officer

Mar 28, 2023, 8:00 AM EDT - 2 years ago

Immuneering Appoints Harold E. Brakewood as Chief Business Officer

Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

Mar 14, 2023, 4:30 PM EDT - 2 years ago

Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

TrendAM
TrendAM Jun. 23 at 11:22 AM
$RBNE $GPUS $IMRX $RELI - Heading for new weekly high !
0 · Reply
Rybod30
Rybod30 Jun. 23 at 11:22 AM
$IMRX Holding $2 gonna be tough…
0 · Reply
TrendAM
TrendAM Jun. 23 at 11:17 AM
$OP Backup again on $RBNE and added $GPUS $IMRX
0 · Reply
TrendAM
TrendAM Jun. 23 at 11:01 AM
$OP added. Added more $GPUS $IMRX $RELI for big rebound play today
0 · Reply
davis8uni
davis8uni Jun. 23 at 3:10 AM
$IMRX
0 · Reply
sam92
sam92 Jun. 22 at 11:25 PM
$IMRX
0 · Reply
winners18
winners18 Jun. 22 at 3:48 PM
$IMRX
1 · Reply
davis8uni
davis8uni Jun. 22 at 1:35 PM
$IMRX
0 · Reply
davis8uni
davis8uni Jun. 21 at 11:27 PM
$IMRX
0 · Reply
StockScanners
StockScanners Jun. 21 at 7:53 PM
$IMRX imrx reached 3.09
0 · Reply
davis8uni
davis8uni Jun. 21 at 12:51 PM
$IMRX
0 · Reply
davis8uni
davis8uni Jun. 21 at 1:32 AM
$IMRX
0 · Reply
HungerGains
HungerGains Jun. 20 at 6:24 PM
$IMRX back to. $3
0 · Reply
sam92
sam92 Jun. 20 at 6:14 PM
$IMRX
0 · Reply
Jaxtyn1989
Jaxtyn1989 Jun. 20 at 6:05 PM
$NUVB plenty cash on hand, FDA approved lung cancer therapy, and insiders bought in $1.1 million worth of stock. $IMRX check out.
1 · Reply
Eruption
Eruption Jun. 20 at 4:47 PM
$IMRX let the slide begin. Fng shorters mfers.
0 · Reply
Tonygunz
Tonygunz Jun. 20 at 4:44 PM
$IMRX Wow! Just dumped
0 · Reply
Tigerlilly11
Tigerlilly11 Jun. 20 at 3:55 PM
$IMRX Zoom out on the dailies on this... this stock has never performed a RS. And we are now, more or less, at the bottom of the curve... which has been curling upward since early May. This ticker is a Buy and Hold!
2 · Reply
BiotechBonesaw
BiotechBonesaw Jun. 20 at 3:50 PM
$IMRX $NUVB great picks! I’ve also been buying more of these today as well as $ALT & $TNXP & $JFBR LOADED FOR BULL! 🐂 ☘️ 🚀
1 · Reply
Bgirl_smirk
Bgirl_smirk Jun. 20 at 3:37 PM
$IMRX holding stilll need 2.80 for moare
0 · Reply
Tigerlilly11
Tigerlilly11 Jun. 20 at 3:22 PM
$IMRX R2G
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jun. 20 at 3:15 PM
$IMRX CEO purchased 21,000 shares at $2.39 for a total of $50,144. Zeskind Benjamin J. now owns 3,197,779 shares. https://ceo-buys.com
0 · Reply